Akari Therapeutics Plc ADR
Akari Therapeutics Plc ADR (AKTX) Covered Calls
Read more
Running AKTX covered calls helps you generate income from Akari Therapeutics Plc ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AKTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If AKTX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AKTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AKTX covered call is worth writing.
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.
| 2027-04-16 | 148 | 10.00 | 49.03 | 0.05 | 3.70 | 334.00 | 49.78 | 122.76 | -0.75 | +0.55 | 1 | 3.65 |
| 2027-07-16 | 239 | 10.00 | 49.03 | 0.25 | 4.50 | 354.00 | 52.76 | 80.57 | -3.73 | +0.62 | 0 | 4.25 |
| 2027-04-16 | 148 | 7.50 | 11.77 | 0.50 | 4.40 | 129.00 | 19.23 | 47.41 | -7.45 | +0.66 | 0 | 3.90 |
| 2027-07-16 | 239 | 7.50 | 11.77 | 0.65 | 5.00 | 144.00 | 21.46 | 32.77 | -9.69 | +0.70 | 0 | 4.35 |
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank—
- Market cap (M$)16
- 52 weeks high-75.51%
- 52 weeks low137.75%
- Analyst recommendationStrong Buy
1.00 - Target price$25.50
255.15% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-08-13
- P/E—
- Future P/E—
- EPS (ttm)-8.84
- EPS growth next 5 years46.54%
As of Nov 20, 2026